Covenant Research and Clinics (United States)

Recent papers from Covenant Research and Clinics (United States)

1. Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction‐associated steatotic liver disease, and other cardio‐kidney‐metabolic conditionsDiabetes Obesity and Metabolism · 2025
2. Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosisJournal of Hepatology · 2024
3. Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 StudyClinical Gastroenterology and Hepatology · 2024
4. A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitisNature Communications · 2023
5. Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitisAlimentary Pharmacology & Therapeutics · 2023
6. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitisJournal of Hepatology · 2022
7. A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetesNature Communications · 2021
8. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASHHepatology · 2020
9. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic SteatohepatitisGastroenterology · 2020